Century Therapeutics, Inc.
IPSCCentury Therapeutics, Inc. in brief
Century Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Philadelphia, Pennsylvania, USA. It was founded in 2018. Its market value was $263 M on 28 October 2026, which makes it the 15,282nd largest listed company in the world and the 2,978th largest in the USA on this site. In the year to December 2025 it had sales of $109 M and a net loss of $10 M. It employs about 78 people and Brent Pfeiffenberger is its chief executive. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol IPSC (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Century Therapeutics, Inc.
●Cutting-edge manufacturing capabilities intended to drive scale advantages and reduce cost of goods sold, or COGs, while minimizing product development and supply risk.
We are leveraging our expertise in cellular reprogramming, differentiation, genetic engineering, and manufacturing to develop therapies with the potential to provide enhanced clinical outcomes compared to existing cell therapy technologies and available therapeutic options. We are unique in the breadth of cell types we can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ ab T cells, or ab iT cells, and iPSC- natural killer cells, or iNK cells. We believe this capability enables optimal matching of cell characteristics to disease indication, ensuring we target the right cell for the right indication.
From the company's annual report filed with the US SEC: read the report
Century Therapeutics, Inc. timeline
- 2018
- 🏁· approximateFounded
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 21 June 2021; shares registered for exchange trading on 14 June 2021.
- 2025
- 💰Record revenue of $109 millionFY2025, the highest of the 4 years on record.
Events of Century Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,868 (Jan 2022) · #3,094 (Dec 2022) · #3,689 (Jul 2023) · #3,248 (Jan 2024) · #1,285 (Mar 2026) · #2,756 (Aug 2026) · #3,006 (Oct 2026) · #2,982 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 2.4×
- Price / book
- 1.7×
- Free cash flow yield
- -39.8%
- Net margin
- -8.8%
- Operating margin
- -15.8%
- Return on equity
- -6.0%
- Liabilities / assets
- 29.0%
- Net debt
- $-74M
- Revenue growth
- +1556.4%
- R&D / revenue
- 87.6%
- Revenue per employee
- $1.4 M
- Profit per employee
- $-123 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $109M | +1556.4% | $-17M | $-10M | -8.8% |
| Dec 2024 | $7M | +194.2% | $-138M | $-127M | -1920.6% |
| Dec 2023 | $2M | -56.9% | $-147M | $-137M | -6101.3% |
| Dec 2022 | $5M | — | $-134M | $-131M | -2517.9% |
| Dec 2021 | — | — | $-95M | $-96M | — |
| Dec 2020 | — | — | $-54M | $-54M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-104M | $1M | $-105M | $-0.14 | — |
| Dec 2024 | $-110M | $0M | $-110M | $-1.61 | — |
| Dec 2023 | $-88M | $14M | $-102M | $-2.30 | — |
| Dec 2022 | $14M | $31M | $-17M | $-2.96 | — |
| Dec 2021 | $-89M | $45M | $-134M | $-2.96 | — |
| Dec 2020 | $-41M | $10M | $-51M | $-7.16 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-23M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 2, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 9, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jun 16, 20268-KCurrent reportDirectors or officers changed
- Jun 12, 20268-KCurrent reportBylaws amended · Shareholder vote
- Jun 8, 20268-KCurrent reportOther events
- May 13, 20268-KCurrent reportResults of operations
- May 13, 202610-QQuarterly report · period to Mar 2026
- Apr 27, 2026DEF 14AProxy statement
Official filings of Century Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $109 M
- Operating income
- $-17 M
- Net income
- $-10 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $224 M
- Total liabilities
- $65 M
- Total equity
- $159 M
As of December-2025
Top 100 institutional investors in Century Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 17,754,430 | 0 (0.00%) | 9.78% | $30 M | Nov 16, 2026 |
| 2 | TCG Crossover Management, LLC | 17,754,430 | 0 (0.00%) | 9.78% | $30 M | Nov 16, 2026 |
| 3 | Versant Venture Management, LLC | 12,166,109 | 0 (0.00%) | 6.70% | $21 M | Nov 13, 2026 |
| 4 | Deep Track Capital, LP | 9,462,645 | 0 (0.00%) | 5.21% | $16 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 8,889,485 | +797,717 (+9.86%) | 4.90% | $15 M | Nov 13, 2026 |
| 6 | RTW Investments, LP | 8,695,652 | 0 (0.00%) | 4.79% | $15 M | Nov 16, 2026 |
| 7 | Venrock Adviser, LLC | 8,695,652 | 0 (0.00%) | 4.79% | $15 M | Nov 16, 2026 |
| 8 | Commodore Capital LP | 8,695,652 | 0 (0.00%) | 4.79% | $15 M | Nov 16, 2026 |
| 9 | Millennium Management LLC | 6,054,973 | +1,859,992 (+44.34%) | 3.33% | $10 M | Nov 16, 2026 |
| 10 | Vanguard Capital Management LLC | 5,692,587 | -11,093 (-0.19%) | 3.13% | $10 M | Nov 13, 2026 |
| 11 | Woodline Partners LP | 5,663,346 | +1,405,816 (+33.02%) | 3.12% | $10 M | Nov 16, 2026 |
| 12 | Balyasny Asset Management L.P. | 5,522,769 | -175 (0.00%) | 3.04% | $9 M | Nov 16, 2026 |
| 13 | Point72 Asset Management, L.P. | 5,109,974 | +129,448 (+2.60%) | 2.81% | $9 M | Nov 16, 2026 |
| 14 | Seven Fleet Capital Management LP | 4,421,739 | +73,913 (+1.70%) | 2.43% | $8 M | Nov 16, 2026 |
| 15 | Trails Edge Capital Partners, LP | 4,134,969 | 0 (0.00%) | 2.28% | $7 M | Nov 16, 2026 |
| 16 | Spruce Street Capital LP | 4,059,054 | 0 (0.00%) | 2.24% | $7 M | Nov 13, 2026 |
| 17 | Adage Capital Partners GP, L.L.C. | 3,789,538 | 0 (0.00%) | 2.09% | $6 M | Nov 16, 2026 |
| 18 | Geode Capital Management, LLC | 2,870,994 | -108,535 (-3.64%) | 1.58% | $5 M | Nov 6, 2026 |
| 19 | Stempoint Capital LP | 2,563,862 | +417,680 (+19.46%) | 1.41% | $4 M | Nov 16, 2026 |
| 20 | Two Sigma Investments, LP | 2,560,953 | -138,060 (-5.12%) | 1.41% | $4 M | Nov 16, 2026 |
| 21 | State Street Corp | 2,513,350 | +670,196 (+36.36%) | 1.38% | $4 M | Nov 12, 2026 |
| 22 | DAFNA Capital Management LLC | 2,386,750 | -13,708 (-0.57%) | 1.31% | $4 M | Nov 16, 2026 |
| 23 | Northern Trust Corp | 1,477,054 | -116,890 (-7.33%) | 0.81% | $3 M | Nov 16, 2026 |
| 24 | Rock Springs Capital Management LP | 1,304,347 | 0 (0.00%) | 0.72% | $2 M | Nov 16, 2026 |
| 25 | Casdin Capital, LLC | 1,228,190 | 0 (0.00%) | 0.68% | $2 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Renaissance Technologies LLC | 1,074,200 | -183,500 (-14.59%) | 0.59% | $2 M | Nov 12, 2026 |
| 27 | Vanguard Portfolio Management LLC | 1,035,026 | +19,643 (+1.93%) | 0.57% | $2 M | Nov 13, 2026 |
| 28 | Longaeva Partners L.P. | 943,418 | New | 0.52% | $2 M | Nov 16, 2026 |
| 29 | UBS Group AG | 804,439 | +572,030 (+246.13%) | 0.44% | $1 M | Nov 10, 2026 |
| 30 | Vanguard Fiduciary Trust Co | 737,585 | +63 (+0.01%) | 0.41% | $1 M | Nov 13, 2026 |
| 31 | Goldman Sachs Group Inc | 460,896 | +310,463 (+206.38%) | 0.25% | $1 M | Nov 16, 2026 |
| 32 | Invesco Ltd. | 403,214 | +21,795 (+5.71%) | 0.22% | $1 M | Nov 12, 2026 |
| 33 | Charles Schwab Investment Management Inc | 378,949 | +82 (+0.02%) | 0.21% | $1 M | Nov 16, 2026 |
| 34 | Dimensional Fund Advisors LP | 318,535 | +47,043 (+17.33%) | 0.18% | $1 M | Nov 4, 2026 |
| 35 | Bank of New York Mellon Corp | 299,014 | 0 (0.00%) | 0.16% | $1 M | Nov 5, 2026 |
| 36 | FMR LLC | 273,260 | +264,266 (+2938.25%) | 0.15% | $0 M | Nov 10, 2026 |
| 37 | American Century Companies Inc | 232,301 | +58,239 (+33.46%) | 0.13% | $0 M | Nov 12, 2026 |
| 38 | Nuveen, LLC | 163,592 | 0 (0.00%) | 0.09% | $0 M | Nov 10, 2026 |
| 39 | Morgan Stanley | 144,719 | +106,265 (+276.34%) | 0.08% | $0 M | Nov 13, 2026 |
| 40 | Spark Investment Management LLC | 128,200 | +69,200 (+117.29%) | 0.07% | $0 M | Nov 13, 2026 |
| 41 | Integrated Quantitative Investments LLC | 127,927 | New | 0.07% | $0 M | Nov 13, 2026 |
| 42 | Rhumbline Advisers | 125,548 | -2,856 (-2.22%) | 0.07% | $0 M | Nov 10, 2026 |
| 43 | Graham Capital Management, L.P. | 120,434 | New | 0.07% | $0 M | Nov 16, 2026 |
| 44 | Squarepoint Ops LLC | 110,398 | +20,249 (+22.46%) | 0.06% | $0 M | Nov 9, 2026 |
| 45 | Deutsche Bank AG\ | 105,095 | -15,139 (-12.59%) | 0.06% | $0 M | Nov 6, 2026 |
| 46 | Price T Rowe Associates Inc /MD/ | 101,164 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 47 | Bank Of America Corp /de/ | 101,113 | -57,780 (-36.36%) | 0.06% | $0 M | Nov 16, 2026 |
| 48 | Raymond James Financial Inc | 91,323 | 0 (0.00%) | 0.05% | $0 M | Nov 12, 2026 |
| 49 | Citadel Advisors LLC | 84,660 | -41,810 (-33.06%) | 0.05% | $0 M | Nov 16, 2026 |
| 50 | Wealth Enhancement Advisory Services, LLC | 78,186 | +356 (+0.46%) | 0.04% | $0 M | Oct 13, 2026 |
| 51 | Royal Bank Of Canada | 77,014 | +70,631 (+1106.55%) | 0.04% | $0 M | Nov 16, 2026 |
| 52 | Jpmorgan Chase & Co | 60,793 | +9,585 (+18.72%) | 0.03% | $0 M | Nov 12, 2026 |
| 53 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 59,542 | +3,032 (+5.37%) | 0.03% | $0 M | Nov 16, 2026 |
| 54 | Tidal Investments LLC | 59,274 | New | 0.03% | $0 M | Nov 13, 2026 |
| 55 | Tema Etfs LLC | 59,274 | New | 0.03% | $0 M | Oct 16, 2026 |
| 56 | MetLife Investment Management, LLC | 55,061 | -21,210 (-27.81%) | 0.03% | $0 M | Nov 16, 2026 |
| 57 | AQR Capital Management LLC | 52,448 | New | 0.03% | $0 M | Nov 16, 2026 |
| 58 | Barclays PLC | 52,168 | +27,468 (+111.21%) | 0.03% | $0 M | Nov 6, 2026 |
| 59 | XTX Topco Ltd | 51,900 | New | 0.03% | $0 M | Nov 16, 2026 |
| 60 | Voleon Capital Management LP | 46,019 | New | 0.03% | $0 M | Nov 16, 2026 |
| 61 | Vanguard Global Advisers, LLC | 45,218 | +602 (+1.35%) | 0.02% | $0 M | Nov 13, 2026 |
| 62 | Legal & General Group Plc | 43,960 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 63 | Police & Firemen's Retirement System of New Jersey | 36,349 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 64 | Public Employees Retirement System Of Ohio | 35,395 | New | 0.02% | $0 M | Nov 16, 2026 |
| 65 | Manufacturers Life Insurance Company, The | 34,485 | -117 (-0.34%) | 0.02% | $0 M | Nov 13, 2026 |
| 66 | Alliancebernstein L.P. | 29,790 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 67 | HarbourVest Partners LLC | 29,018 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 68 | BNP Paribas Financial Markets | 28,031 | +2,468 (+9.65%) | 0.02% | $0 M | Nov 12, 2026 |
| 69 | Parametrica Management Ltd | 27,840 | 0 (0.00%) | 0.02% | $0 M | Oct 27, 2026 |
| 70 | Voya Investment Management LLC | 24,067 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 71 | Wells Fargo & Company/mn | 23,964 | -124,951 (-83.91%) | 0.01% | $0 M | Nov 16, 2026 |
| 72 | New York State Common Retirement Fund | 22,700 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 73 | Quadrant Private Wealth Management, LLC | 20,022 | 0 (0.00%) | 0.01% | $0 M | Nov 4, 2026 |
| 74 | Prudential Financial Inc | 18,595 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 75 | ProShare Advisors LLC | 15,474 | -663 (-4.11%) | 0.01% | $0 M | Oct 29, 2026 |
| 76 | Victory Capital Management Inc | 14,022 | -79 (-0.56%) | 0.01% | $0 M | Nov 10, 2026 |
| 77 | Centiva Capital, LP | 13,994 | New | 0.01% | $0 M | Nov 13, 2026 |
| 78 | Legato Capital Management LLC | 12,423 | New | 0.01% | $0 M | Nov 10, 2026 |
| 79 | CIBC Bancorp USA Inc. | 12,184 | New | 0.01% | $0 M | Nov 13, 2026 |
| 80 | Xponance LLC | 11,565 | -204 (-1.73%) | 0.01% | $0 M | Nov 3, 2026 |
| 81 | Qube Research & Technologies Ltd | 11,418 | New | 0.01% | $0 M | Nov 13, 2026 |
| 82 | Ameritas Investment Partners, Inc. | 11,185 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 83 | Susquehanna International Group, LLP | 10,605 | -105,187 (-90.84%) | 0.01% | $0 M | Nov 16, 2026 |
| 84 | Russell Investments Group, Ltd. | 10,258 | +403 (+4.09%) | 0.01% | $0 M | Nov 6, 2026 |
| 85 | FNY Investment Advisers, LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 16, 2026 |
| 86 | Tower Research Capital LLC (TRC) | 7,031 | -5,452 (-43.68%) | 0.00% | $0 M | Nov 16, 2026 |
| 87 | Citigroup Inc | 6,094 | -50,907 (-89.31%) | 0.00% | $0 M | Nov 4, 2026 |
| 88 | Sterling Capital Management LLC | 2,431 | -53 (-2.13%) | 0.00% | $0 M | Oct 22, 2026 |
| 89 | California State Teachers Retirement System | 1,697 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 90 | SBI Securities Co., Ltd. | 1,200 | -18 (-1.48%) | 0.00% | $0 M | Oct 22, 2026 |
| 91 | GAMMA Investing LLC | 1,064 | New | 0.00% | $0 M | Oct 8, 2026 |
| 92 | Nisa Investment Advisors, LLC | 883 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 93 | Jacobi Capital Management LLC | 800 | New | 0.00% | $0 M | Nov 5, 2026 |
| 94 | Mark Sheptoff Financial Planning, LLC | 500 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 95 | Fortitude Family Office, LLC | 294 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 96 | Allworth Financial LP | 183 | New | 0.00% | $0 M | Nov 17, 2026 |
| 97 | Arax Advisory Partners | 99 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 98 | Group One Trading LLC | 46 | New | 0.00% | $0 M | Nov 10, 2026 |
| 99 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 40 | New | 0.00% | $0 M | Nov 16, 2026 |
| 100 | Caitong International Asset Management Co., Ltd | 17 | -18 (-51.43%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Century Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 4.34 M | $11 M | 2.4% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.90 M | $7 M | 1.6% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.22 M | $3 M | 0.67% | <0.01% | +1.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.34 M | $3 M | 0.74% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 1.11 M | $3 M | 0.61% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 560,308 | $1 M | 0.31% | <0.01% | +124% | May 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 549,930 | $1 M | 0.30% | 0.20% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 413,323 | $1 M | 0.23% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 299,452 | $1 M | 0.16% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 230,383 | $1 M | 0.13% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 200,453 | $0 M | 0.11% | <0.01% | +112% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 172,406 | $0 M | 0.09% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 164,276 | $0 M | 0.09% | <0.01% | +119% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 163,592 | $0 M | 0.09% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 131,018 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 125,318 | $0 M | 0.07% | 0.01% | +531% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 112,474 | $0 M | 0.06% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 121,810 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 90,500 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 94,822 | $0 M | 0.05% | <0.01% | +53% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 76,004 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 79,415 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 65,179 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 63,739 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 58,625 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 45,800 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 43,232 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 37,139 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 34,920 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 27,732 | $0 M | 0.02% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 27,200 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 25,848 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 26,905 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 19,334 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 18,837 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 18,582 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 17,800 | $0 M | <0.01% | <0.01% | +0.6% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 21,278 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 16,539 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 15,270 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 14,432 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 14,101 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 11,185 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 9,930 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 9,930 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 9,855 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 10,846 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 8,797 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 8,621 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 9,543 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 9,378 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 9,238 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 8,854 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 7,447 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 5,662 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 5,633 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 4,978 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,284 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 3,111 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 2,954 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 768 | $0 M | <0.01% | <0.01% | +5.9% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 61 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Century Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Brent PfeiffenbergerPresident and CEO, Director | Shares withheld for tax | -31,172 | $1.650 | $51 K | 3.60 M | Form 4 |
| filed | Douglas CarrSVP Finance & Operations | Sell | -266 | $1.519 | $404 | 502,641 | Form 4 |
| filed | Douglas CarrSVP Finance & Operations | Sell | -1,658 | $1.930 | $3 K | 502,907 | Form 4 |
| filed | Gregory RussottiSee Remarks | Sell | -2,587 | $1.930 | $5 K | 509,198 | Form 4 |
| filed | Brent PfeiffenbergerPresident and CEO, Director | Shares withheld for tax | -13,850 | $1.940 | $27 K | 3.63 M | Form 4 |
| filed | Gregory RussottiSee Remarks | Sell | -534 | $2.050 | $1 K | 511,785 | Form 4 |
| filed | Douglas CarrSVP Finance & Operations | Sell | -254 | $2.050 | $521 | 504,565 | Form 4 |
| filed | Brent PfeiffenbergerPresident and CEO, Director | Shares withheld for tax | -463 | $2.110 | $977 | 3.63 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Century Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 2.516-for-1 split
Trading halts
- 2025-03-19 20:00 UTC, code T3, resumed 20:30 UTC
Fails to deliver
- : 66,416 shares at $1.45
- : 42,457 shares at $1.58
- : 47,479 shares at $1.37
- : 40,630 shares at $1.38
- : 4,353 shares at $1.48
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Century Therapeutics, Inc. scorecard#
Passes 8 of the 18 checks that could be worked out: strongest in growth (3 of 4), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median2.4×Price to sales 2.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-39.8%Free cash flow is -39.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 4
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- ✓Revenue up more than 5% a year over three years175.9%175.9% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median175.9%175.9% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.14 vs -1.61Diluted EPS -0.14 in fiscal 2025 against -1.61 the year before (report's currency).
- ✓Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$54 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 5
- ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-15.8%-15.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-6.0%-6.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-15.8%-15.8% in fiscal 2025 against -2573.7% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities6.0×Current ratio 5.97 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-1.74Z-score -1.74 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year10.1%Diluted shares up 10.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Century Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -15.8% | -60.5% | |
| Net margin | -8.8% | -68.9% | |
| Return on equity | -6.0% | -61.0% | |
| Revenue growth, 3 years a year | 175.9% | 12.9% | |
| Free cash flow margin | -95.9% | -61.5% |
3of 7on the Piotroski tests of financial strength
- Net loss of $10 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$105 million.
- The share count rose 10.1% in the year.
Century Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 109+1557%100% | 6.6+195%100% | 2.2−57.0%100% | 5.2—100% | — | — | |
| Research and development | 96−10.8%87.6% | 107+15.7%1628% | 93−4.6%4148% | 97+28.5%1869% | 76+90.6%— | 40—— | |
| General and administrative | 24−27.6%22.0% | 33−4.5%503% | 35+8.9%1553% | 32+65.6%613% | 19+103%— | 9.5—— | |
| Operating expenses | 126−12.6%116% | 145−2.7%2196% | 149+7.0%6657% | 139+46.5%2674% | 95+76.0%— | 54—— | |
| Operating income | −17—−15.8% | −138—−2096% | −147—−6557% | −134—−2574% | −95—— | −54—— | |
| Interest expense and finance costs | — | — | 0.5−46.9%24.2% | 1.0r1.4−20.2%19.6% | 1.3+235%— | 0.4—— | |
| Other non-operating income (expense) | 7.6−43.0%7.0% | 13+13.7%203% | 12+293%526% | 3.0—57.5% | −0.9−378%— | 0.3—— | |
| Income before tax | −9.6—−8.8% | −125—−1894% | −135—−6031% | −131—−2517% | −96—— | −54—— | |
| Income tax | −0.1−104%−0.1% | 1.8−4.8%27.2% | 1.9+1967%84.2% | 0.1+112%1.8% | 0.0—— | — | |
| Net income including minority interests | −9.6—−8.8% | −127—−1921% | −137—−6115% | −131—−2518% | −96—— | −54—— | |
| Net income attributable to shareholders | −9.6—−8.8% | −127—−1921% | −137—−6115% | −131—−2518% | −96—— | −54—— | |
| Earnings per share, basic | -0.14—— | -1.61—— | -2.30—— | -2.27—— | -2.96—— | -7.16—— | |
| Earnings per share, diluted | -0.14—— | -1.61—— | -2.30r-2.27—— | -2.96r-2.27—— | -2.96—— | -7.16—— | |
| Shares, weighted average (basic) | 87+10.1%— | 79+32.6%— | 59+2.7%— | 58+78.3%— | 32+333%— | 7.5—— | |
| Shares, weighted average (diluted) | 87+10.1%— | 79+32.6%— | 59r58+83.1%— | 32r580.0%— | 32+333%— | 7.5—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 62+5.8%27.6% | 58+23.5%16.5% | 47−43.8%13.1% | 84+49.3%17.3% | 56+107%12.9% | 27—25.5% | |
| Short-term investments | 55−57.8%24.7% | 131+4.3%37.0% | 125−45.8%34.8% | 231+38.9%47.5% | 166+243%38.1% | 49—45.5% | |
| Other current assets | 3.7−23.2%1.6% | 4.8+203%1.3% | 1.6−60.8%0.4% | 4.0+1501%0.8% | 0.3−2.3%0.1% | 0.3—0.2% | |
| Current assets | 121−37.8%54.0% | 194+9.6%54.9% | 177−44.6%49.1% | 320+40.1%65.7% | 228+190%52.2% | 79—73.8% | |
| Property, plant and equipment | 50−19.5%22.4% | 62−13.3%17.6% | 72−13.4%19.9% | 83+42.8%17.0% | 58+277%13.3% | 15—14.4% | |
| Right-of-use (leased) assets | 16−43.8%7.2% | 29+40.9%8.1% | 20−29.6%5.6% | 29+144%5.9% | 12+26.2%2.7% | 9.4—8.8% | |
| Other intangible assets | 340.0%15.3% | 34—9.7% | — | — | — | — | |
| Long-term investments | — | 31−65.4%8.7% | 89+71.8%24.7% | 52−61.8%10.7% | 136+12807%31.1% | 1.1—1.0% | |
| Total assets | 224−36.7%100% | 353−2.1%100% | 361−25.9%100% | 487+11.2%100% | 437+310%100% | 107—100% | |
| Accounts payable | 4.8+55.2%2.1% | 3.1+12.2%0.9% | 2.7−49.7%0.8% | 5.5−28.2%1.1% | 7.6−6.0%1.7% | 8.1—7.6% | |
| Debt due within a year | — | — | — | 6.5+526%1.3% | 1.0—0.2% | — | |
| Current liabilities | 20−84.4%9.0% | 130+627%36.7% | 18−40.1%4.9% | 30+90.5%6.1% | 16+29.3%3.6% | 12—11.3% | |
| Long-term debt | — | — | — | 3.7−58.0%0.8% | 8.9−7.6%2.0% | 9.6—9.0% | |
| Lease liabilities (non-current) | 40−17.8%18.0% | 49+4.9%13.9% | 47+20.6%12.9% | 39+166%8.0% | 15+24.7%3.3% | 12—10.9% | |
| Total liabilities | 65−66.2%29.0% | 192+9.0%54.3% | 176−4.3%48.8% | 184+347%37.8% | 41+23.1%9.4% | 33—31.3% | |
| Retained earnings | −792—−354% | −782—−221% | −656—−182% | −519—−107% | −388—−88.7% | −292—−274% | |
| Shareholders' equity | 159−1.5%71.0% | 161−12.7%45.7% | 185−39.0%51.2% | 303−23.6%62.2% | 396—90.6% | −106—−99.7% | |
| Total liabilities and equity | 224−36.7%100% | 353−2.1%100% | 361−25.9%100% | 487+11.2%100% | 437+310%100% | 107—100% | |
| Shares outstanding | 88+2.0%— | 86+42.3%— | 60+9.7%— | 55r55−5.9%— | 58r55+682%— | 7.5—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 6.8−46.1%6.3% | 13−13.2%193% | 15+37.1%654% | 11+129%205% | 4.7+432%— | 0.9—— | |
| Cash from operating activities | −104—−95.2% | −110—−1671% | −88−729%−3953% | 14—270% | −89—— | −41—— | |
| Capital expenditure | −0.8—−0.8% | −0.2—−2.3% | −14—−615% | −31—−589% | −45—— | −9.8—— | |
| Cash from investing activities | 108+126%98.5% | 47−22.3%721% | 61—2735% | −13—−253% | −298—— | −23—— | |
| Debt repaid | — | — | −10—−458% | — | — | — | |
| Shares issued | 0.2+22.7%0.2% | 0.1−72.7%2.1% | 0.5+49.6%23.1% | 0.3+62.0%6.6% | 0.2—— | — | |
| Cash from financing activities | 0.2−99.8%0.2% | 75—1132% | −9.7−136%−435% | 27−93.5%522% | 418+776%— | 48—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | 0*−100%— | 0*−100%— | 0*−100%— | 109+12668%100% | 4.2*+1457%100% | 0.8—100% | 0.8—100% | 0.9—100% | 0.3*—100% | |
| Research and development | 74−10.1%— | 18+150400%— | 20−27.0%— | 17−35.6%— | 20*−33.0%— | 0.0−100.0%— | 27−1.3%— | 27+13.5%24.3% | 29*+31.8%704% | 27—3442% | 27—3530% | 23—2739% | 22*—8319% | |
| General and administrative | 20−33.6%— | 7.1+4.6%— | 5.8−25.9%— | 6.6−21.8%— | 1.0*−87.7%— | 6.8−18.2%— | 7.8−6.0%— | 8.4−3.8%7.7% | 7.8*−9.7%186% | 8.4—1056% | 8.3—1077% | 8.7—1023% | 8.6*—3205% | |
| Operating expenses | 106−28.0%— | 25−30.2%— | 37+5.4%— | 24−32.3%— | 21*−50.2%— | 36+1.5%— | 35−2.4%— | 35+8.8%32.1% | 41*−5.8%993% | 36—4498% | 36—4608% | 32—3762% | 44*—16429% | |
| Operating income | −106—— | −25—— | −37—— | −24−132%— | −21*—— | −36—— | −35—— | 74—67.9% | −37*—−893% | −35—−4398% | −35—−4508% | −31—−3662% | −44*—−16329% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | — | 1.1r0*—403% | |
| Other non-operating income (expense) | 7.2−21.9%— | 1.8+3.0%— | 2.0−6.9%— | 2.0−14.5%— | 1.4*−52.7%— | 1.7−52.1%— | 2.1−40.5%— | 2.4−26.6%2.2% | 3.0*−14.5%71.6% | 3.6—449% | 3.6—463% | 3.2—380% | 3.5*—1304% | |
| Income before tax | — | — | — | — | −19*—— | −34—— | −33—— | 77—70.1% | −34*—−822% | −31—−3949% | −31—−4045% | −28—−3282% | −40*—−15025% | |
| Income tax | — | — | — | — | — | — | — | — | 1.8*—42.6% | −0.0—−1.0% | 0.0—2.9% | 0.0—0.1% | −0.9*—−324% | |
| Net income including minority interests | −99—— | −23*—— | −35*—— | −22−128%— | −19*—— | −34*—— | −33*—— | 77—70.1% | −36*—−864% | −31*—−3947% | −31*—−4048% | −28—−3282% | −39*—−14701% | |
| Net income attributable to shareholders | −99—— | −23—— | −35—— | −22−128%— | −19*—— | −34—— | −33—— | 77—70.1% | −36*—−864% | −31—−3948% | −31—−4048% | −28—−3282% | −39*—−14701% | |
| Earnings per share, basic | — | -0.11—— | -0.17—— | -0.11−112%— | — | -0.40—— | -0.38—— | 0.89—— | — | -0.37—— | -0.38—— | -0.45—— | — | |
| Earnings per share, diluted | — | -0.11—— | -0.17—— | -0.11−112%— | — | -0.40—— | -0.38—— | 0.89—— | — | -0.37—— | -0.38—— | -0.45—— | — | |
| Shares, weighted average (basic) | 206+139%— | 206+139%— | 206+139%— | 193+125%— | — | 86+2.1%— | 86+5.1%— | 86+38.1%— | — | 85—— | 82—— | 62—— | — | |
| Shares, weighted average (diluted) | 206+139%— | 206+139%— | 206+139%— | 193+125%— | — | 86+2.1%— | 86+5.1%— | 86+38.2%— | — | 85—— | 82—— | 62—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 45—17.1% | 45−18.9%17.1% | 50−12.7%17.3% | 51−1.6%15.6% | 62+5.8%27.6% | 56+5.6%22.7% | 57+37.2%20.0% | 52+10.8%16.4% | 58+23.5%16.5% | 53—13.5% | 41—10.0% | 47—13.4% | 47—13.1% | |
| Short-term investments | 72—27.5% | 72−6.5%27.5% | 70−29.2%24.4% | 84−26.0%25.6% | 55−57.8%24.7% | 77−46.9%31.6% | 99−36.1%34.8% | 113−22.0%35.9% | 131+4.3%37.0% | 146—37.4% | 155—37.2% | 145—41.7% | 125—34.8% | |
| Other current assets | 5.5—2.1% | 5.5+11.1%2.1% | 5.1+16.9%1.8% | 4.2−6.1%1.3% | 3.7−23.2%1.6% | 5.0−37.2%2.0% | 4.3−38.9%1.5% | 4.5−42.2%1.4% | 4.8+203%1.3% | 7.9—2.0% | 7.1—1.7% | 7.8—2.2% | 1.6—0.4% | |
| Current assets | 123—46.7% | 123−10.9%46.7% | 125−22.1%43.5% | 139−18.0%42.6% | 121−37.8%54.0% | 138−33.2%56.3% | 160−21.3%56.3% | 170−15.1%53.7% | 194+9.6%54.9% | 206—53.0% | 203—48.9% | 200—57.3% | 177—49.1% | |
| Property, plant and equipment | 33—12.5% | 33−38.9%12.5% | 34−39.1%12.0% | 48−20.0%14.6% | 50−19.5%22.4% | 54−17.7%21.9% | 57−18.4%19.9% | 60−13.7%18.9% | 62−13.3%17.6% | 65—16.8% | 69—16.7% | 69—19.8% | 72—19.9% | |
| Right-of-use (leased) assets | 13—5.1% | 13−19.1%5.1% | 14−51.3%4.7% | 21−25.7%6.4% | 16−43.8%7.2% | 17−42.5%6.8% | 28−2.9%9.7% | 28+46.2%8.9% | 29+40.9%8.1% | 29—7.4% | 29—6.9% | 19—5.5% | 20—5.6% | |
| Goodwill | — | — | — | — | — | — | — | — | — | 4.7—1.2% | 5.1—1.2% | — | — | |
| Other intangible assets | 34—13.0% | 340.0%13.0% | 340.0%11.9% | 340.0%10.5% | 340.0%15.3% | 34+1.2%14.0% | 34+2.7%12.0% | 34—10.8% | 34—9.7% | 34—8.7% | 33—8.0% | — | — | |
| Long-term investments | 57—21.7% | 57—21.7% | 77+2780%27.0% | 82+297%25.2% | — | — | 2.7−96.3%0.9% | 21−64.2%6.6% | 31−65.4%8.7% | 47—12.0% | 73—17.6% | 58—16.6% | 89—24.7% | |
| Total assets | 263—100% | 263+7.3%100% | 287+0.8%100% | 327+3.5%100% | 224−36.7%100% | 245−37.0%100% | 285−31.6%100% | 316−9.4%100% | 353−2.1%100% | 389—100% | 416—100% | 349—100% | 361—100% | |
| Accounts payable | 3.0—1.1% | 3.0+14.0%1.1% | 4.8+50.3%1.7% | 3.2−11.8%1.0% | 4.8+55.2%2.1% | 2.6+0.7%1.1% | 3.2−4.5%1.1% | 3.6+4.1%1.1% | 3.1+12.2%0.9% | 2.6—0.7% | 3.4—0.8% | 3.4—1.0% | 2.7—0.8% | |
| Current liabilities | 14—5.3% | 14−36.2%5.3% | 15+0.8%5.3% | 14−6.5%4.2% | 20−84.4%9.0% | 22+11.1%9.0% | 15−22.0%5.3% | 15−9.7%4.6% | 130+627%36.7% | 20—5.1% | 19—4.6% | 16—4.6% | 18—4.9% | |
| Lease liabilities (non-current) | 34—12.8% | 34−18.3%12.8% | 35−25.7%12.1% | 44−8.1%13.5% | 40−17.8%18.0% | 41−19.0%16.8% | 47−11.6%16.4% | 48+8.0%15.1% | 49+4.9%13.9% | 51—13.1% | 53—12.7% | 44—12.7% | 47—12.9% | |
| Total liabilities | 53—20.1% | 53−23.0%20.1% | 55−26.9%19.0% | 62−17.8%18.9% | 65−66.2%29.0% | 68−64.6%27.9% | 75−61.5%26.3% | 75−55.9%23.8% | 192+9.0%54.3% | 193—49.6% | 194—46.7% | 171—49.0% | 176—48.8% | |
| Retained earnings | −872—−332% | −872—−332% | −848—−296% | −814—−249% | −792—−354% | −773—−316% | −738—−259% | −706—−224% | −782—−221% | −746—−192% | −715—−172% | −684—−196% | −656—−182% | |
| Shareholders' equity | 210—79.9% | 210+19.1%79.9% | 232+10.7%81.0% | 265+10.1%81.1% | 159−1.5%71.0% | 176−9.9%72.1% | 210−5.5%73.7% | 240+35.2%76.2% | 161−12.7%45.7% | 196—50.4% | 222—53.3% | 178—51.0% | 185—51.2% | |
| Total liabilities and equity | 263—100% | 263+7.3%100% | 287+0.8%100% | 327+3.5%100% | 224−36.7%100% | 245−37.0%100% | 285−31.6%100% | 316−9.4%100% | 353−2.1%100% | 389—100% | 416—100% | 349—100% | 361—100% | |
| Shares outstanding | 181—— | 181+109%— | 181+109%— | 180+109%— | 88+2.0%— | 87+2.3%— | 86+2.1%— | 86+42.8%— | 86+42.3%— | 85—— | 85—— | 60—— | 60—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 6.1−25.1%— | 1.4+62.0%— | 2.0−12.2%— | 1.4−40.4%— | 1.3*−51.1%— | 0.9−73.1%— | 2.2−36.6%— | 2.4−24.4%2.2% | 2.7*−25.3%63.7% | 3.3—419% | 3.5—454% | 3.2—375% | 3.6*—1329% | |
| Cash from operating activities | −83—— | −22*—— | −20*—— | −25—— | −16*—— | −26*—— | −28*—— | −35—−31.7% | −24*—−580% | −28*—−3582% | −27*—−3545% | −30—−3538% | −26*—−9787% | |
| Capital expenditure | — | −0.5*—— | −0.7*—— | −0.6—— | — | −0.2*—— | −0.3*—— | −0.5—−0.4% | — | — | −0.3*—−34.4% | −0.5—−63.0% | −1.0*—−366% | |
| Cash from investing activities | −55−147%— | 18*−29.0%— | 18*−45.4%— | −113−503%— | 22*−26.9%— | 25*−37.1%— | 33*—— | 28+142%25.6% | 31*+64.5%733% | 39*—4956% | −34*—−4392% | 12—1350% | 19*—6941% | |
| Debt repaid | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Shares issued | 0.7—— | 0.1*—— | 0.3*—— | 0.2+68.3%— | 0.1*—— | 0*−100%— | 0*−100%— | 0.1−67.2%0.1% | −0.6*—−14.4% | 0.3*—34.5% | 0.1*—13.5% | 0.4—42.8% | −0.4*—−133% | |
| Cash from financing activities | 127—— | 0.1*—— | 0.3*—— | 127+105419%— | 0.1*—— | 0*−100%— | 0*−100%— | 0.1−99.3%0.1% | −0.6*—−14.4% | 0.3*—34.5% | 57*—7354% | 18—2128% | −0.4*—−133% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Century Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Single reportable segment$109 M100%+1556%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Century Therapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office2 subsidiaries | — |
| 🇳🇱 Netherlands | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Century Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Restructuring 1 · Directors and officers 7 · Material agreement 1 · Agreement ended 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersResults announced | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 acquisitions, $40 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Clade Therapeutics, Inc | 2024 | — | $40 M | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Century Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $120 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Scientist, Discovery BiologyBioinformatics Scientists | 1 | $120 K |
Where: Watertown, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $120 K | 1 |
| FY2025 | 1 | 1 | $85 K | 1 |
| FY2022 | 1 | 1 | $129 K | 1 |
| FY2020 | 4 | 4 | $85 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Century Therapeutics LLC
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 51% of workforce | Restructuring planSEC 8-K | “The Company expects to implement a net reduction of its employee headcount by approximately 51% (the “ RIF ”).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Century Therapeutics, Inc. compares in Biotechnology
- Market cap$263 M · higher than 49% of 726
- Revenue$109 M · higher than 69% of 647
- Net margin-8.8% · higher than 65% of 408
- Revenue growth1556.5% · higher than 99% of 438
- Price / sales2.4× · lower than 81% of 339
- Price / book1.7× · lower than 63% of 534
- FCF yield-39.8% · higher than 29% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Century Therapeutics, Inc.🇺🇸 | $263 M | — | -8.8% | +1556.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Century Therapeutics, Inc.? Verify and update this profile — free
Show Century Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.